ARTICLE | Clinical News
CP-4126: Completed Phase II enrollment
April 2, 2012 7:00 AM UTC
Clavis completed enrollment of about 360 patients with metastatic pancreatic cancer in the open-label, international, pivotal Phase II LEAP trial comparing weekly 1,250 mg/m 2 IV CP-4126 for 3 out of ...